Assembly Biosciences (ASMB) Income from Non-Controlling Interests (2016 - 2018)
Assembly Biosciences' (ASMB) quarterly Income from Non-Controlling Interests came in at $25931.0 in Q3 2018, down 57.55% year-on-year from $61081.0 in Q3 2017, and down 79.62% quarter-over-quarter from $127234.0 in Q2 2018.
Assembly Biosciences (ASMB) Income from Non-Controlling Interests (2016 - 2018) Analysis & Trends
Assembly Biosciences' Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at $25931.0 for Q3 2018.
- On a quarterly basis, Income from Non-Controlling Interests fell 57.55% year-over-year to $25931.0 in Q3 2018; TTM through Sep 2018 was $286722.0, a 34.93% decrease from a year earlier, with the FY2017 full-year figure at $466483.0, down 33.62% from the prior year.
- Income from Non-Controlling Interests eased to $25931.0 in Q3 2018 per ASMB's latest filing, from $127234.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $273573.0 in Q3 2016 and bottomed at $23016.0 in Q1 2018.
- The 3-year median for Income from Non-Controlling Interests is $127234.0 (2018), against an average of $122314.6.
- Across the five-year window, Income from Non-Controlling Interests jumped 30.47% in 2017 and tumbled 83.23% in 2018, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $84722.0 in 2016, then jumped by 30.47% to $110541.0 in 2017, then sank by 76.54% to $25931.0 in 2018.
- Per Business Quant, the three latest ASMB Income from Non-Controlling Interests figures stand at $25931.0 (Q3 2018), $127234.0 (Q2 2018), and $23016.0 (Q1 2018).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | - |
| 10 | Assembly Biosciences | 444.73 Mn | 218.13 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 25,931.00 |
| Jun 30, 2018 | 127,234.00 |
| Mar 31, 2018 | 23,016.00 |
| Dec 31, 2017 | 110,541.00 |
| Sep 30, 2017 | 61,081.00 |
| Jun 30, 2017 | 157,613.00 |
| Mar 31, 2017 | 137,248.00 |
| Dec 31, 2016 | 84,722.00 |
| Sep 30, 2016 | 273,573.00 |
| Jun 30, 2016 | 142,675.00 |
| Mar 31, 2016 | 201,827.00 |